Longboard Pharmaceuticals, Inc. (LBPH)

21.96 +0.66 (+3.10%) At close: 04:00PM EDT

Longboard Pharmaceuticals, Inc.

4275 Executive Square
Suite 950
La Jolla, CA 92037
United States
858-789-9283
https://www.longboardpharma.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 50

Key executives

Name	Title	Pay	Exercised	Year born
Mr. Kevin R. Lind	President, CEO, Secretary & Director	1.07M	N/A	1976
Ms. Brandi L. Roberts CPA, M.B.A.	Executive VP & CFO	662.65k	N/A	1974
Dr. Randall E. Kaye M.D.	Executive VP & Chief Medical Officer	717.95k	N/A	1962
Mr. Chadwick J. Orevillo MPH	Executive VP & Head of Operations	N/A	N/A	N/A
Megan E. Knight	VP & Head of Investor Relations	N/A	N/A	N/A
Mr. Steven W. Spector J.D.	Executive VP, Head of Business Development & General Counsel	N/A	N/A	1965
Dr. Anne M. Danks Ph.D.	VP & Head of Nonclinical Research & Development	N/A	N/A	N/A
Mr. Gus Cardenas	VP & Head of Quality Assurance	N/A	N/A	N/A
Dr. Marco Peters Ph.D.	VP & Head of Translational Science	N/A	N/A	N/A
Dr. Dewey McLin Ph.D.	VP & Head of Medical Affairs	N/A	N/A	N/A

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Longboard Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel and transformative medicines for neurological diseases. The company develops bexicaserin (LP352), which has completed Phase 1b/2a clinical trial for the treatment of seizures associated with developmental and epileptic encephalopathies. It also develops LP659, an S1P receptor modulator for the treatment of neurological diseases. The company was formerly known as Arena Neuroscience, Inc. and changed its name to Longboard Pharmaceuticals, Inc. in October 2020. Longboard Pharmaceuticals, Inc. was incorporated in 2020 and is based in La Jolla, California.

Corporate governance

Longboard Pharmaceuticals, Inc.’s ISS governance QualityScore as of 29 April 2024 is 8. The pillar scores are Audit: 8; Board: 8; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.